Skip to main content

Advertisement

Log in

Neurofibromatosis type 1 (NF1) and pheochromocytoma: prevalence, clinical and cardiovascular aspects

  • Original Paper
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

The aim of the study was to evaluate the prevalence of pheochromocytoma (PHEO) in patients with neurofibromatosis type 1 (NF1), and to analyze the behavior of some anthropometric and cardiovascular parameters. In 48 consecutive NF1 patients, urinary metanephrines and vanillylmandelic acid excretion were assessed. The body mass index (BMI), waist circumference (WC), ambulatory blood pressure monitoring (ABPM), echocardiography and ultrasound carotid arterial wall evaluation were performed. In NF1 patients, 11 (29.3%) had arterial hypertension, 7 (14.6%) had a PHEO. Four (57%) NF1 patients with PHEO were symptomatic at the diagnosis. In PHEO-NF1 patients, we revealed a lower BMI and WC values with respect to NF1 patients without PHEO and normal subjects (NSs) (p < 0.05), respectively. The nocturnal non-dipping pattern at the ABPM was present in 40.4% of NF1 patients, and in particular this phenomenon was present in PHEO-NF1 patients (71.4%). Left ventricular mass index and intima media thickness were significantly higher in NF1 patients as compared to NS (p < 0.05), particularly in NF1-PHEO patients (p < 0.05). In conclusions, these findings revealed high prevalence of PHEO in NF1 patients and suggest that, in addition to blood pressure, humoral factors (increased sympathetic activity or neurofibromin), influence the pathogenesis of remodeling of cardiovascular system.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Bausch B, Borozdin W, Mautner VF et al (2007) Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. J Clin Endocrinol Metab 92(7):2784–2792

    Article  PubMed  CAS  Google Scholar 

  2. Bravo EL, Tagle R (2003) Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev 24:539–553

    Article  PubMed  CAS  Google Scholar 

  3. Ceruti M, Petramala L, Cotesta D et al (2006) Ambulatory blood pressure monitoring in secondary arterial hypertension due to adrenal diseases. J Clin Hypertens 8:642–648

    Article  Google Scholar 

  4. Cichowski K, Jacks T (2001) NF1 tumor suppressor gene function: narrowing the GAP. Cell 104:593–604

    Article  PubMed  CAS  Google Scholar 

  5. Cotesta D, Erlic Z, Petramala L et al (2008) Coincidence of neurofibromatosis Type 1 and multiple endocrine neoplasia type 2. Endocrinologist 18:277–281

    Article  Google Scholar 

  6. Denolle T, Chatellier G, Julien J et al (1993) Left ventricular mass and geometry before and after etiologic treatment in renovascular hypertension, aldosterone-producing adenoma, and pheochromocytoma. Am J Hypertens 6:907–913

    PubMed  CAS  Google Scholar 

  7. Ferner RE, Huson SM, Thomas N et al (2007) Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 44(2):81–88

    Article  PubMed  CAS  Google Scholar 

  8. Friedman JM (1999) Epidemiology of neurofibromatosis type 1. Am J Med Genet 89:1–6

    Article  PubMed  CAS  Google Scholar 

  9. Gabriel KR (1997) Neurofibromatosis. Curr Opin Pediatr 9:89–93

    Article  PubMed  CAS  Google Scholar 

  10. Goldberg NS, Roenigk RK (1996) Neurofibromatosis, tuberous sclerosis, and other neurocutaneous discorde. In: Wintronb BU (ed) Cutaneous medicine and surgery: an interpretated program in dermatology. WB Saunders, Philadelpfia, pp 1729–1741

  11. Goldstein DS, Eisenhofer G, Flynn JA et al (2004) Diagnosis and localization of pheochromocytoma. Hypertension 43:907–910

    Article  PubMed  CAS  Google Scholar 

  12. Gutmann DH, Aylsworth A, Carey JC et al (1997) The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278:51–57

    Article  PubMed  CAS  Google Scholar 

  13. Hansen TW, Jeppesen J, Rasmussen S, Ibsen H, Torp-Pedersen C (2006) Ambulatory blood pressure monitoring and risk of cardiovascular disease: a population based study. Am J Hypertens 19(3):243–250

    Article  PubMed  Google Scholar 

  14. Heineke J, Molkentin JD (2006) Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7:589–600

    Article  PubMed  CAS  Google Scholar 

  15. Heniford BT, Arca MJ, Walsh RM, Gill IS (1999) Laparoscopic adrenalectomy for cancer. Semin Surg Oncol 16(4):293–306

    Article  PubMed  CAS  Google Scholar 

  16. Huson SM, Compston DA, Clark P et al (1989) A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet 26:704–711

    Article  PubMed  CAS  Google Scholar 

  17. Ito Y, Fujimoto Y, Obara T (1992) The role of epinephrine, norepinephrine, and dopamine in blood pressure disturbances in patients with pheochromocytoma. World J Surg 16:759–763

    Article  PubMed  CAS  Google Scholar 

  18. Jenne DE, Tinschert S, Reimann H et al (2001) Molecular characterization and gene content of breakpoint boundaries in patients with neurofibromatosis type 1 with 17q11.2 microdeletions. Am J Hum Genet 69:516–527

    Article  PubMed  CAS  Google Scholar 

  19. Kurpad AV, Khan K, Calder AG, Elia M (1994) Muscle and whole body metabolism after norepinephrine. Am J Physiol 266:E877–E884

    PubMed  CAS  Google Scholar 

  20. La Batide-Alanore A, Chatellier G, Plouin PF (2003) Diabetes as a marker of pheochromocytoma in hypertensive patients. J Hypertension 21:1703–1707

    Article  Google Scholar 

  21. Lakkis MM, Epstein JA (1998) Neurofibromin modulation of Ras activity is required for normal endocardial-mesenchymal transformation in the developing heart. Development 125:4359–4367

    PubMed  CAS  Google Scholar 

  22. Lenders JW, Eisenhofer G, Mannelli M et al (2005) Phaeochromocytoma. Lancet 366:665–675

    Article  PubMed  Google Scholar 

  23. Mancia G, Ferrari A, Gregorini L et al (1983) Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res 53:96–104

    PubMed  CAS  Google Scholar 

  24. Mannelli M, Ianni L, Cilotti A et al (1999) Pheochromocytoma in Italy: a multicentric retrospective study. Eur J Endocrinol 141:619–624

    Article  PubMed  CAS  Google Scholar 

  25. Millar-Craig MW, Bishop CN, Raftery EB (1978) Circadian variation of blood-pressure. Lancet 1:795–797

    Article  PubMed  CAS  Google Scholar 

  26. Norton KK, Xu J, Gutmann DH (1995) Expression of the neurofibromatosis I gene product, neurofibromin, in blood vessel endothelial cells and smooth muscle. Neurobiol Dis 2:13–21

    Article  PubMed  CAS  Google Scholar 

  27. O’Brien E, Sheridan J, O’Malley K (1988) Dippers and non-dippers. Lancet 2:397

    Article  PubMed  Google Scholar 

  28. Pacak K, Linehan WM, Eisenhofer G et al (2001) Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 134:315–329

    PubMed  CAS  Google Scholar 

  29. Palatini P, Penzo M, Racioppa A et al (1992) Clinical relevance of nighttime blood pressure and of daytime blood pressure variability. Arch Intern Med 152:1855–1860

    Article  PubMed  CAS  Google Scholar 

  30. Rizzoni D, Muiesan ML, Porteri E et al (1998) Relations between cardiac and vascular structure in patients with primary and secondary hypertension. J Am Coll Cardiol 32:985–992

    Article  PubMed  CAS  Google Scholar 

  31. Routledge F, McFetridge-Durdle J (2007) Non-dipping blood pressure patterns among individuals with essential hypertension: a review of the literature. Eur J Cardiovasc Nurs 6:9–26

    Article  PubMed  Google Scholar 

  32. Shub C, Cueto-Garcia L, Sheps SG et al (1986) Echocardiographic findings in pheochromocytoma. Am J Cardiol 57:971–975

    Article  PubMed  CAS  Google Scholar 

  33. Tedesco MA, Di Salvo G, Natale F, Pergola V, Calabrese E, Grassia C, Ratti G, Iarussi D, Iacono A, Calabrò R, Lama G (2002) The heart in neurofibromatosis type 1: an echocardiographic study. Heart J. 143:883–888

    Article  Google Scholar 

  34. Walther MM, Herring J, Enquist E et al (1999) von Recklinghausen’s disease and pheochromocytomas. J Urol 162:1582–1586

    Article  PubMed  CAS  Google Scholar 

  35. Xu J, Ismat FA, Wang T et al (2009) Cardiomyocyte-specific loss of neurofibromin promotes cardiac hypertrophy and dysfunction. Circ Res 105:304–311

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Claudio Letizia.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zinnamosca, L., Petramala, L., Cotesta, D. et al. Neurofibromatosis type 1 (NF1) and pheochromocytoma: prevalence, clinical and cardiovascular aspects. Arch Dermatol Res 303, 317–325 (2011). https://doi.org/10.1007/s00403-010-1090-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-010-1090-z

Keywords

Navigation